Ozempic Injection (Semaglutide) 0.25mg

Ozempic contains semaglutide, a GLP-1 receptor agonist used with diet and exercise to improve blood glucose control in adults with insufficiently controlled type 2 diabetes. Treatment with Ozempic may also result in weight reduction in eligible patients. It is administered by subcutaneous injection according to the prescribed treatment regimen.

Key Features & Specifications

• Active ingredient: Semaglutide
• Medicine class: GLP-1 receptor agonist
• Administration: Subcutaneous injection
• Dosing: Once weekly
• Strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Use: Type 2 diabetes management alongside diet and exercise
• Manufacturer: Novo Nordisk
• Availability: Prescription medicine